Advanced searches left 3/3

Cardiac Transthyretin - Crossref

Summarized by Plex Scholar
Last Updated: 05 September 2022

* If you want to update the article please login/register

Myocardial Scintigraphy in Diagnosing Cardiac Transthyretin Amyloidosis

Myocardial scintigraphy with technetium-99 million pyrophosphate is a minimally invasive method that can tell the difference between transthyretin amyloidosis and light-chain amyloidosis. We present a situation in which we assisted determine the amyloidosis type in a 74-year-old man with cardiac amyloidosis and multiple previous admissions for acute decompensated heart failure in a 74-year-old man. Patients with increasing abdominal girth and bilateral lower extremity edema were detected in the patient. His acute decompensated heart disease with cardiorenal syndrome and his decompensated cirrhosis were treated by a guideline-directed medical therapy. A typical free u03b light-chain ratio of 2. 24 has been established two years ago, with the patient's age, predominantly cardiac involvement, unremarkable serum protein electrophoresis findings, and a presumptive diagnosis of ATTR cardiomyopathy. This case shows that technetium-99 million pyrophosphate scintigraphy can help diagnose ATTR cardiomyopathy and identifying patients that may benefit from disease-modifying therapy.

Source link: https://doi.org/10.14503/thij-20-7379


Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Background: In cardiac amyloidosis, the incidence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis than in immunoglobulin light chain amyloidosis. Patients with transthyretin cardiac amyloidosis have reduced atrial function, according to our findings. Methods: Echocardiographic strain analysis was performed with speckle tracking in cardiac amyloidosis patients in our Amyloidosis Expert Center's Amyloidosis Patients. Results: The results of 53 cardiac amyloidosis patients were reviewed. Patients with Transthyretin cardiac amyloidosis patients were older and had more left ventricular hypertrophy than immunoglobulin light chain cardiac amyloidosis patients. Conclusions: Transthyretin cardiac amyloidosis patients had lower left atrial reservoir function when compared to immunoglobulin light chain cardiac amyloidosis patients, although left atrial geometry was similar. The effect of impaired left atrial dysfunction in transthyretin cardiac amyloidosis in transthyretin cardiac amyloidosis on atrial fibrillation and prognosis is well documented, according to further studies.

Source link: https://doi.org/10.3390/biomedicines10081768


A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study

obstructive coronary artery disease artery disease in some patients with cardiac transthyretin amyloidosis with obstructive epicardial coronary artery disease. Also in the absence of epicardial CAD, few studies found that coronary microvascular dysfunction was highly prevalent in subjects with cardiac amyloidosis. After 24 months of therapy, the aim of this study is to reveal coronary microvascular dysfunction and to go deeper with analysis of Tafamidis' effects on microvascular dysfunction. The inclusion of adult patients with confirmed ATTR cardiomyopathy in three major referral centers' nuclear medicine departments and treated with Tafamidis will be included. Between baseline and 24 months after treatment, the key findings of this research will be the variation in stress and rest myocardial blood flow and flow reserve between baseline and 24 months after treatment. The Orleans Hospital Research Committee and the Sud-Mediterrane IV Regional Ethics Committee have approved the study, which has been published.

Source link: https://doi.org/10.3389/fmed.2022.978293


Transthyretin cardiac amyloidosis

Abstract Transthyretin cardiac amyloidosis is a common cause of heart disease and mortality worldwide. Amyloid fibril formation is a result of age-related impairment of homoeostatic pathways in wild-type ATTR amyloidosis or destabilizing mutations in variant ATTR amyloidosis. An outbreak of cardiac amyloidosis in the current age of 17 per 100 000, which was almost due to misdiagnosis and underestimated, according to large-scale studies in the United States. Patients hospitalized for HF with preserved ejection fractions can die as a result of mortality in ATTRwt and ATTRv amyloidosis, as well as mortality in ATTRwt and ATTRv amyloidosis. ATTR can be distinguished from light chain amyloidosis by tracing with u2018bone u2019 tracer samosis as well as biochemical tests.

Source link: https://doi.org/10.1093/cvr/cvac119


Mitochondrial Oxidative Stress Induces Cardiac Fibrosis in Obese Rats through Modulation of Transthyretin

Male Wistar rats were fed a standard diet or a high-fat diet and treated with MitoQ or MitoQ in drinking water for seven weeks. According to Protesteomic results, HFD animals had an increase in cardiac transthyretin protein levels, an effect that was not prevented by MitoQ treatment in obese rats. In cardiac fibroblasts, TTR stimulated collagen I production and BiP. In summary, the findings show that TTR plays a role in cardiac fibrosis formation as a result of obesity as well as the beneficial effects of mitochondrial antioxidant therapy.

Source link: https://doi.org/10.3390/ijms23158080


Reverse Remodeling Following Valve Replacement in Coexisting Aortic Stenosis and Transthyretin Cardiac Amyloidosis

Background: Anterior stenosis and transthyretin cardiac amyloidosis are two related pathologies that are increasingly recognized. We set out to characterize reverse remodeling in AS-ATTR and comparison to lone AS, and compared to lone AS. Methods: Consecutive patients who needed transcatheter aortic valve replacement underwent ATTR testing by blinded 99mTc-DPD bone scintigraphy before intervention. DPD and a lack of monoclonal protein were both attributed to ATTR's disease. Both groups experienced significant health improvement by a New York Heart Association functional class 12 months after TAVR, respectively. Despite this, AS-ATTR was more symptomatic with elevated residual NT-proBNP levels. Left ventricular mass regression only for lone AS, not AS-ATTR. In AS-ATTR, however, an increase in regional longitudinal strain demonstrated a base-to-apex gradient, although all but apical segments improved in lone AS. AS-ATTR transforms into a lone ATTR cardiomyopathy phenotype after AS care.

Source link: https://doi.org/10.1161/circimaging.122.014115


RWT/SaVR—A Simple and Highly Accurate Measure Screening for Transthyretin Cardiac Amyloidosis

Cardiac amyloidosis is underdiagnosed disease, and simple techniques for accurate diagnosis are recommended. Material and methods: We analyzed 102 patients with left ventricular hypertrophy in ATTR-CA and 65 patients with left ventricular hypertrophy, none of whom had septal thickness > 14 mm. Conclusion: RWT/SaVR has been used to diagnose ATTR-CA in patients with septal thickness > 14 mm, which we can confirm with absolute certainty.

Source link: https://doi.org/10.3390/jcm11144120


Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis

The misfolding of TTR monomers and their accumulation within tissues as amyloid fibres is characteristic of ATTR amyloidosis. Current therapeutic options are dependent on the blockade of TTR development, TTR stabilization, and TTR stabilization to preserve the native structure of TTR, amyloid degradation, or tissue transplantation. Amyloid seeds are important in the promotion of amyloid formation and dissemination. Seeds in tissues may be used as biomarkers for early disease stages from months to years before symptoms appear, indicating that seeds in tissues may potentially be used as biomarkers for the early disease stages.

Source link: https://doi.org/10.1007/s10741-022-10237-7


Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

Transthyretin cardiac amyloidosis, also known as transthyretin cardiomyopathy, is a poorly recognized disease with delayed diagnosis and poor prognosis. Methods of Attraction From the Korean National Health Insurance Service's 2013 and 2018 patients with ATTR-CM between 2013 and 2018 were included in the study, which included the entire population. With ATTR CM, the Kaplanu2013Meier survival curve and years of potential life lost from the general population were estimated for disease burden. Results The ATTR-CM registry was developed in the United States, a total of 175 newly diagnosed patients were identified. Hypertension was the most common cardiac sign, according to the most typical non-cardiac manifestation, musculoskeletal disease. Mean medical expenses at the time of the pre-cohort entry date were much higher than those at the pre-cohort entry date. The median YPLL was 13. 0, with a 3. 53 years from the first diagnosis of ATTR-CM, and the mean YPLL was 3. 53 years. Patients with ATTR-CM had short lives and high medical bills, making them a poor choice.

Source link: https://doi.org/10.1186/s13023-022-02425-3


Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?

PNP-specific PNP scores were significantly higher in patients with cATTR and additional diagnosis of PNP relative to patients without a prescription. DPD uptake in the subcutaneous fat of the left axillar region of cATTR patients was considerable higher in cATTR patients in cATTR patients compared to patients without cATTR. Conclusions DPD bone scintigraphy is a valuable tool for identifying patients with cATTR and a risk for PNP as a result of increased DPD soft tissue uptake, according to the study.

Source link: https://doi.org/10.1007/s12350-022-02986-7

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions